Technical Analysis for CYCC - Cyclacel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 0.63 -3.41% -0.02
CYCC closed down 3.41 percent on Friday, November 1, 2024, on 17 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 11
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hammer Candlestick Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 22 hours ago
Down 5% about 22 hours ago
Down 3% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
New 52 Week Low about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cyclacel Pharmaceuticals, Inc. Description

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Inflammatory Diseases Cancer Cell Autoimmune And Inflammatory Disease Human Cancers Cell Cycle Cyclacel Cyclin Dependent Kinase Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Checkpoint Cyclin Dependent Kinase 2 Sapacitabine Seliciclib

Is CYCC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.122
52 Week Low 0.6
Average Volume 1,279,006
200-Day Moving Average 1.76
50-Day Moving Average 0.98
20-Day Moving Average 0.89
10-Day Moving Average 0.88
Average True Range 0.20
RSI (14) 34.64
ADX 35.72
+DI 40.24
-DI 22.01
Chandelier Exit (Long, 3 ATRs) 1.88
Chandelier Exit (Short, 3 ATRs) 1.21
Upper Bollinger Bands 1.31
Lower Bollinger Band 0.47
Percent B (%b) 0.19
BandWidth 95.24
MACD Line -0.09
MACD Signal Line -0.05
MACD Histogram -0.0395
Fundamentals Value
Market Cap 663.82 Thousand
Num Shares 1.06 Million
EPS -29.85
Price-to-Earnings (P/E) Ratio -0.02
Price-to-Sales 6.32
Price-to-Book 0.56
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.68
Resistance 3 (R3) 0.68 0.66 0.67
Resistance 2 (R2) 0.66 0.64 0.66 0.67
Resistance 1 (R1) 0.64 0.64 0.63 0.65 0.67
Pivot Point 0.62 0.62 0.62 0.62 0.62
Support 1 (S1) 0.61 0.61 0.60 0.61 0.59
Support 2 (S2) 0.58 0.60 0.59 0.58
Support 3 (S3) 0.57 0.58 0.58
Support 4 (S4) 0.57